
Please try another search
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company’s lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. It has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
Name | Age | Since | Title |
---|---|---|---|
Michael Philip Dybbs | 49 | 2019 | Independent Director |
Paul J. Hastings | 64 | 2018 | CEO & Director |
Ali Behbahani | 49 | 2015 | Independent Chairman |
Angela M. Thedinga | 43 | 2022 | Independent Director |
George Vratsanos | 61 | 2024 | Independent Director |
Simeon John George | 48 | 2020 | Independent Director |
Zachary Scheiner | 48 | 2020 | Independent Director |
Leone D. Patterson | 63 | 2020 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review